Aptose Biosciences (APS) Competitors

C$1.64
-0.01 (-0.61%)
(As of 05/3/2024 ET)

APS vs. RVX, ATE, AEZS, MBX, BCT, HBP, and TH

Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Resverlogix (RVX), Antibe Therapeutics (ATE), Aeterna Zentaris (AEZS), Microbix Biosystems (MBX), BriaCell Therapeutics (BCT), Helix BioPharma (HBP), and Theratechnologies (TH). These companies are all part of the "biotechnology" industry.

Aptose Biosciences vs.

Aptose Biosciences (TSE:APS) and Resverlogix (TSE:RVX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends and earnings.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptose Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Resverlogix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Resverlogix received 98 more outperform votes than Aptose Biosciences when rated by MarketBeat users. Likewise, 84.01% of users gave Resverlogix an outperform vote while only 72.11% of users gave Aptose Biosciences an outperform vote.

CompanyUnderperformOutperform
Aptose BiosciencesOutperform Votes
212
72.11%
Underperform Votes
82
27.89%
ResverlogixOutperform Votes
310
84.01%
Underperform Votes
59
15.99%

9.8% of Aptose Biosciences shares are owned by institutional investors. 20.2% of Aptose Biosciences shares are owned by insiders. Comparatively, 43.2% of Resverlogix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Resverlogix is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/A-C$51.21M-C$10.49-0.16
ResverlogixN/AN/A-C$12.82M-C$0.05-1.20

Aptose Biosciences has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500. Comparatively, Resverlogix has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500.

In the previous week, Aptose Biosciences' average media sentiment score of 0.00 equaled Resverlogix'saverage media sentiment score.

Company Overall Sentiment
Aptose Biosciences Neutral
Resverlogix Neutral

Resverlogix's return on equity of 0.00% beat Aptose Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptose BiosciencesN/A -225.00% -102.23%
Resverlogix N/A N/A -37.10%

Summary

Resverlogix beats Aptose Biosciences on 7 of the 10 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APS vs. The Competition

MetricAptose BiosciencesBiotechnology IndustryMedical SectorTSE Exchange
Market CapC$25.76MC$133.99MC$5.01BC$5.33B
Dividend Yield0.39%3.55%2.89%5.53%
P/E Ratio-0.16186.57165.6623.61
Price / SalesN/A16,704.192,456.561,631.61
Price / Cash1.6011.7849.7379.47
Price / Book1.596.194.883.10
Net Income-C$51.21M-C$20.08MC$103.85MC$293.33M
7 Day Performance-3.53%3.29%3.93%0.04%
1 Month Performance-14.14%2.25%-3.04%-0.96%
1 Year Performance124.66%-1.07%4.24%20.24%

Aptose Biosciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RVX
Resverlogix
0 of 5 stars
C$0.06
flat
N/A-58.6%C$16.33MN/A-1.2019Upcoming Earnings
High Trading Volume
ATE
Antibe Therapeutics
0 of 5 stars
C$0.30
flat
N/AN/AC$15.54MC$9.71M-0.8411
AEZS
Aeterna Zentaris
0 of 5 stars
C$2.60
-2.6%
N/A+180.3%C$12.64MC$4.50M-0.5611Upcoming Earnings
News Coverage
Gap Up
High Trading Volume
MBX
Microbix Biosystems
0 of 5 stars
C$0.35
+3.0%
N/A-11.8%C$47.11MC$22.42M11.50N/AUpcoming Earnings
BCT
BriaCell Therapeutics
0 of 5 stars
N/AN/AN/AC$47.30MN/A-2.7716
HBP
Helix BioPharma
0 of 5 stars
C$0.22
flat
N/A+2.5%C$50.48MN/A-7.339News Coverage
Gap Down
TH
Theratechnologies
0.9977 of 5 stars
C$1.77
-1.1%
C$5.50
+210.7%
+39.8%C$81.39MC$81.76M-1.43103

Related Companies and Tools

This page (TSE:APS) was last updated on 5/5/2024 by MarketBeat.com Staff

From Our Partners